Oncoheroes today announced its organizational membership into the Coalition Against Childhood Cancer, known as CAC2, a collaborative network of organizations and individuals supporting and servicing the childhood cancer community. CAC2 effectively advances a variety of childhood cancer causes by unifying the childhood cancer community through broad-based coordinated action and collaboration that leverages the strengths and expertise of its individual members and minimizes duplication of effort.

The primary values underlying CAC2 are to put the children and their families first in everything they do and to support organizations active in the fight against childhood cancer.

“We want to acknowledge the tremendous effort done by the CAC2 to bring together key stakeholders in childhood cancer. We believe that companies like Oncoheroes, exclusively dedicated to developing drugs for childhood cancer, have to support CAC2’s mission and stay connected with foundations, patient associations, and researchers working in the field of pediatric oncology“, stated Ricardo Garcia, Oncoheroes’ CEO.

The childhood cancer community is a multi-faceted and passionate collection of small, medium-sized, and large organizations and committed individuals who fight childhood cancer and provide support to the children and families affected by childhood cancer in a myriad of ways.

CAC2 was established in 2011 by a grassroots movement to bridge some of the natural fragmentation that arises from having such a diverse community. It received approval by the IRS as a 501(c)3 organization, effective June 21, 2013. More information is available by visiting the website CAC2.orgor by emailing info@CAC2.org.

The list of CAC2 member organizations is located here.

Subscribirse al Directorio
Escribir un Artículo

Últimas Noticias

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Destacadas

Entrevista con Dámaso Molero, director ...

by 3P Biopharmaceuticals

Dámaso Molero:" Creo que en Latinoamérica habrá negocio en el d...

FishChoice: una herramienta para evaluar...

by Universitat Rovira i Virgili

El grupo de investigación TecnATox de la Universidad Rovira i Virgili...

Diapositiva de Fotos